Sarepta Therapeutics Announces Positive Data for Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Sarepta Therapeutics reported positive data for SRP-5051, their next-generation exon skipping agent designed for individuals amenable to skipping Exon 51.

In part B of the Phase 2 MOMENTURM study, ambulatory and non-ambulatory individuals who received the high dose of 30 mg/kg once every 4 weeks had an average dystrophin expression of 5.17% at 28 weeks.

This is significantly higher levels of dystrophin than seen with Sarepta’s FDA-approved agent, Exondys 51 (eteplirsen). Compared to Exondys 51, SRP-5051 contains a peptide designed to increase the ability of the exon-skipping agent to get into cells, and is dosed once every four weeks rather than every week.

In terms of safety concerns, hypomagnesemia has been previously identified with SRP-5051 treatment, and in this study was monitored and managed by having participants take magnesium supplements prophylactically.

The press release, which contains more information about both the low and high-dose cohorts, is HERE

@sareptatherapeutics said that they are requesting a pre-NDA meeting with the FDA for later this year (Q3 2024).

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.